EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta‐Analysis

Anna Rattu iD, Piers Dixey iD, David Charles, Chris Brightling iD, Kian Fan Chung iD, Apostolos Bossios iD, Arnaud Bourdin iD, Ratko Djukanovic iD, Sven-Erik Dahlén, Louise Fleming iD, Rekha Chaudhuri, Erik Melén iD und 11 weitere

Allergy · 2026-01 · 81 (1) · 24-55

DOI: 10.1111/all.70031 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Allergy, online erschienen am 16.09.2025. Verfasst von Anna Rattu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU), University of Southampton.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologics are effective for severe asthma, but not all patients benefit equally. There is an urgent need to understand which biologic works best for which patient. We systematically searched for predictors of response to biologics (except omalizumab) for severe asthma in four bibliographic databases and two trial registries from 1990 to 2024. Two reviewers screened records, extracted data, and assessed risk of bias using a modified CASP checklist. Data were synthesized narratively, and certainty of evidence assessed using the modified GRADE framework. Comparable studies were meta‐analyzed using a random‐effects model. From 5853 records, 21 studies were identified investigating predictors of anti‐IL5/5Rα, 4Rα, and anti‐TSLP response. We found predominantly ‘moderate’ to ‘high’ quality evidence that raised blood eosinophil counts (≥ 300 cells/μL), FeNO levels (> 40 ppb), lack of or low OCS dose (< 10 mg/day), and better asthma control predict biologic response. Evidence for the predictive value of other characteristics was limited and mostly ‘low’ quality. Key reasons for downgrading the evidence were heterogeneous response definitions and imprecision. No data were identified for the pediatric population or biologics targeting the non‐T2 pathway. Outside of traditional inflammatory and clinical variables, there is an unmet need for universally applicable predictors of biologic response for severe asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsAnti-Asthmatic AgentsHumansSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

biologicspredictive biomarkersresponsesevere asthma

Substanzen

Biological ProductsAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • National Heart Lung Institute, Imperial College, London, UK.
  • Royal Brompton Hospital, London, UK.
  • Academic Clinical Medicine, Southampton General Hospital, Southampton, UK.
  • Institute for Lung Health, Leicester NIHR BRC, University of Leicester, Leicester, UK.

ORCID-Profile: Anna Rattu, Piers Dixey, Chris Brightling, Kian Fan Chung, Apostolos Bossios, Arnaud Bourdin, Ratko Djukanovic, Louise Fleming, Erik Melén, Antoine Deschildre, Gerard H Koppelman, Andrew Exley, Clare Williams, Ekaterina Khaleva, Graham Roberts

Förderung

  • Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU)
  • University of Southampton

Zitieren

APA

Rattu, A., Dixey, P., Charles, D., Brightling, C., Chung, K. F., Bossios, A., Bourdin, A., Djukanovic, R., Dahlén, S. E., Fleming, L., Chaudhuri, R., Melén, E., Deschildre, A., Pilette, C., Koppelman, G. H., Exley, A., Anckers, F., Miller, S., Nielsen, H., …, & 3TR consortium Respiratory Work Package (2026). Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta‐Analysis. Allergy, 81(1), 24-55. https://doi.org/10.1111/all.70031

Vancouver

Rattu A, Dixey P, Charles D, Brightling C, Chung KF, Bossios A, et al. Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta‐Analysis. Allergy. 2026;81(1):24-55. doi:10.1111/all.70031

BibTeX
@article{Rattu2026,
  author = {Rattu, Anna and Dixey, Piers and Charles, David and Brightling, Chris and Chung, Kian Fan and Bossios, Apostolos and Bourdin, Arnaud and Djukanovic, Ratko and Dahlén, Sven-Erik and Fleming, Louise and Chaudhuri, Rekha and Melén, Erik and Deschildre, Antoine and Pilette, Charles and Koppelman, Gerard H and Exley, Andrew and Anckers, Freja and Miller, Sarah and Nielsen, Hanna and Williams, Clare and Khaleva, Ekaterina and Roberts, Graham and 3TR consortium Respiratory Work Package, 3TR consortium Respiratory Work Package},
  title = {Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta‐Analysis},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {1},
  pages = {24--55},
  doi = {10.1111/all.70031}
}
Kostenlos starten →